Abstract
Introduction
This study aimed to provide the first real-world description of the characteristics, treatments, dosing patterns, and early outcomes of patients with ALK-positive non-small cell lung cancer (NSCLC) who received ceritinib in US clinical practice.
Methods
US oncologists provided data from medical charts of adult patients diagnosed with locally advanced or metastatic ALK-positive NSCLC who received ceritinib following crizotinib. Patient characteristics, treatment patterns, ceritinib dosing, early outcomes, and occurrence of gastrointestinal adverse events (AEs) by dose and instructions on food intake were assessed, and Kaplan–Meier analysis was used to describe clinician-defined progression-free survival (PFS) on ceritinib.
Results
Medical charts of 58 ALK-positive NSCLC patients treated with ceritinib were reviewed (median age 63 years; 41% male; 21% with prior chemotherapy experience). At ceritinib initiation, 44 patients had multiple distant metastases, most commonly in the liver (60%), bone (53%), and brain (38%). Initial ceritinib dose varied: 71% received 750 mg, 19% 600 mg, and 10% 450 mg. Although median follow-up after ceritinib initiation was short (3.8 months), most patients achieved either a complete or partial response (69%) on ceritinib, regardless of metastatic sites present at initiation or initial dose. Median PFS on ceritinib was 12.9 months. 17% of patients had a gastrointestinal AE reported during follow-up. The majority of events occurred in patients instructed to fast; no patients instructed to take a lower dose of ceritinib with food reported gastrointestinal AEs.
Conclusion
These early findings of ceritinib use in clinical practice suggest that ceritinib is effective at treating crizotinib-experienced ALK-positive NSCLC patients, regardless of metastatic sites or initial dose, and dosing ceritinib with food may lead to fewer gastrointestinal AEs. Future studies with larger sample size and longer follow-up are warranted, including an ongoing randomized trial to assess the gastrointestinal tolerability of ceritinib 450 and 600 mg with low-fat meals.
Funding
Novartis Pharmaceutical Corporation.
Similar content being viewed by others
References
American Cancer Society. Cancer facts and figures, 2016. http://www.cancer.org/acs/groups/content/@editorial/documents/document/acspc-044552.pdf. Accessed Aug 2016.
Boland JM, Erdogan S, Vasmatzis G, et al. Anaplastic lymphoma kinase immunoreactivity correlates with ALK gene rearrangement and transcriptional up-regulation in non-small cell lung carcinomas. Hum Pathol. 2009;40(8):1152–8.
Inamura K, Takeuchi K, Togashi Y, et al. EML4–ALK fusion is linked to histological characteristics in a subset of lung cancers. J Thorac Oncol. 2008;3(1):13–7.
Koivunen JP, Mermel C, Zejnullahu K, et al. EML4–ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res. 2008;14(13):4275–83.
Perner S, Wagner PL, Demichelis F, et al. EML4–ALK fusion lung cancer: a rare acquired event. Neoplasia. 2008;10(3):298–302.
Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer. Nature. 2007;448(7153):561–6.
Wong DW, Leung EL, So KK, et al. The EML4–ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. Cancer. 2009;115(8):1723–33.
Solomon BJ, Mok T, Kim D-W, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 2014;371(23):2167–77.
Solomon B, Varella-Garcia M, Camidge DR. ALK gene rearrangements: a new therapeutic target in a molecularly defined subset of non-small cell lung cancer. J Thorac Oncol. 2009;4(12):1450–4.
Shackelford RE, Vora M, Mayhall K, Cotelingam J. ALK-rearrangements and testing methods in non-small cell lung cancer: a review. Genes Cancer. 2014;5(1–2):1–14.
Wu J, Savooji J, Liu D. Second- and third-generation ALK inhibitors for non-small cell lung cancer. J Hematol Oncol. 2016;9(1):1–7.
Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 2013;368(25):2385–94.
Chun SG, Choe KS, Iyengar P, Yordy JS, Timmerman RD. Isolated central nervous system progression on crizotinib: an achilles heel of non-small cell lung cancer with EML4–ALK translocation? Cancer Biol Ther. 2012;13(14):1376–83.
Sasaki T, Koivunen J, Ogino A, et al. A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. Cancer Res. 2011;71(18):6051–60.
Shaw AT, Solomon B. Anaplastic lymphoma kinase (ALK) fusion oncogene positive non-small cell lung cancer. 2016. http://www.uptodate.com/contents/anaplastic-lymphoma-kinase-alk-fusion-oncogene-positive-non-small-cell-lung-cancer. Accessed Sept 2016.
Food and Drug Administration (FDA). FDA approves ceritinib. 2014. http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm395386.htm. Accessed Sept 2016.
Food and Drug Administration (FDA). FDA approves new oral therapy to treat ALK-positive lung cancer. 2015. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm476926.htm. Accessed Sept 2016.
Clinicaltrials.gov. A dose escalation/expansion study of LDK378 in patients with tumors characterized by genetic abnormalities in anaplastic lymphoma kinase. https://clinicaltrials.gov/ct2/show/NCT01283516. Accessed Sept 2016.
Raedler LA. Zykadia (Ceritinib) approved for patients with crizotinib-resistant ALK-positive non–small-cell lung cancer. Am Health Drug Benefits. 2015;8(Spec Feature):163–6.
Khozin S, Blumenthal GM, Zhang L, et al. FDA approval: ceritinib for the treatment of metastatic anaplastic lymphoma kinase-positive non-small cell lung cancer. Clin Cancer Res. 2015;21(11):2436–9.
Clinicaltrials.gov. Pharmacokinetic and safety study of lower doses of ceritinib taken with a low-fat meal versus 750 mg of ceritinib in the fasted state in adult patients with (ALK-positive) metastatic non-small cell lung cancer (NSCLC). https://clinicaltrials.gov/ct2/show/NCT02299505. Accessed Sept 2016.
Felip E, Crino L, Kim DW, et al. 141PD: whole body and intracranial efficacy of ceritinib in patients (pts) with crizotinib (CRZ) pretreated, ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC) and baseline brain metastases (BM): results from ASCEND-1 and ASCEND-2 trials. J Thorac Oncol. 2016;11(4 Suppl):S118–9.
Kim DW, Mehra R, Tan DS, et al. Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial. Lancet Oncol. 2016;17(4):452–63.
Lau YY, Gu W, Lin T, Song D, Yu R, Scott JW. Effects of meal type on the oral bioavailability of the ALK inhibitor ceritinib in healthy adult subjects. J Clin Pharmacol. 2016;56(5):559–66.
Crino L, Ahn MJ, De Marinis F, et al. Multicenter phase II study of whole-body and intracranial activity with ceritinib in patients with ALK-rearranged non-small-cell lung cancer previously treated with chemotherapy and crizotinib: results from ASCEND-2. J Clin Oncol. 2016;34(24):2866–73.
Bendaly E, et al. Monitoring for and characteristics of crizotinib progression: a chart review of ALK+ non-small cell lung cancer patients. J Thorac Oncol. 2017;12(1):S1163.
Acknowledgements
Novartis Pharmaceutical Corporation sponsored this study (LDK 2015-03). The sponsor participated in conception and design of the study, analysis and interpretation of data, drafting of the manuscript or revising it critically for important intellectual content, and decision to submit the manuscript for publication. Novartis Pharmaceutical Corporation funded article-processing charges. Cinzia Metallo, Ph.D., an employee of Analysis Group, Inc., provided medical writing assistance. All authors made substantial contributions to all of the following: conception and design of the study, analysis and interpretation of data, drafting of the manuscript or revising it critically for important intellectual content. All authors had full access to all of the data in this study and take complete responsibility for the integrity of the data and accuracy of the data analysis. All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this manuscript, take responsibility for the integrity of the work as a whole, and have given final approval for the version to be published.
Disclosures
Philip Galebach is an employee of Analysis Group, Inc., a company that has received consulting fees from Novartis Pharmaceuticals Corporation. Iryna Bocharova is an employee of Analysis Group, Inc., a company that has received consulting fees from Novartis Pharmaceuticals Corporation. Rebekah Foster is an employee of Analysis Group, Inc., a company that has received consulting fees from Novartis Pharmaceuticals Corporation. Annie Guérin is an employee of Analysis Group, Inc., a company that has received consulting fees from Novartis Pharmaceuticals Corporation. Alexander R. Macalalad is a former employee of Analysis Group, Inc. Anand A. Dalal is an employee of Novartis Pharmaceuticals Corporation. Kenneth Culver is an employee of Novartis Pharmaceuticals Corporation. Medha Sasane is an employee of Novartis Pharmaceuticals Corporation. Edmond Bendaly has received consultancy fees from Novartis Pharmaceuticals Corporation.
Compliance with Ethics Guidelines
This study did not collect any patient-identifying information and was exempt from review by the Western Institutional Review Board. This article does not contain any new studies with human or animal subjects performed by any of the authors.
Data Availability
The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.
Previous Presentation
A synopsis of the current research was presented in poster format at the IASLC Chicago Multidisciplinary Symposium in Thoracic Oncology, which took place in Chicago, IL, September 22–24, 2016 and in poster format at the IASLC 17th World Conference on Lung Cancer in Vienna, Austria, December 4–7, 2016.
Author information
Authors and Affiliations
Corresponding author
Additional information
Enhanced content
To view enhanced content for this article go to http://www.medengine.com/Redeem/1B08F060551E142A.
Rights and permissions
About this article
Cite this article
Bendaly, E., Dalal, A.A., Culver, K. et al. Treatment Patterns and Early Outcomes of ALK-Positive Non-Small Cell Lung Cancer Patients Receiving Ceritinib: A Chart Review Study. Adv Ther 34, 1145–1156 (2017). https://doi.org/10.1007/s12325-017-0527-6
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12325-017-0527-6